Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity

Pediatric Blood and Cancer

Volumn 51, Issue 3, 2008, Pages 327-333

  Germanakis, Ioannis ^a   Anagnostatou, Nikol ^a   Kalmanti, Maria ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Biological markers; Cardiotoxicity after cancer therapy; Diagnostic tools; Late effects; Natriuretic peptides; Troponin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; NATRIURETIC FACTOR; RAZOXANE; TROPONIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCINTIANGIOGRAPHY; SIDE EFFECT; SOLID TUMOR; SUDDEN DEATH;

ANTHRACYCLINES; BIOLOGICAL MARKERS; CARDIOTOXINS; CHILD; DRUG MONITORING; DRUG TOXICITY; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; TROPONIN;

EID: 48249098888     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21633     Document Type: Review

References (64)

1. Gatta G, Capocaccia R, Coleman MP, et al. Childhood cancer survival in Europe and the United States. Cancer 2002;95:1767-1772.
2. Bleyer WA. The impact of childhood cancer in the United States and the world. Cancer J Clin 1990;40:354-367.
3. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982;9:23-33.
4. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001;19:3163-3172.
5. Van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006;42:3191-3198.
6. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002;13:819-829.
7. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005;112:e154-e235.
8. Yeh Eth, Tong At, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-3131.
9. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the Children's Cancer Study Group. Pediatrics 1992;89:942-949.
10. Apple FS, Wu AH, Jaffe AS, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation 2007; 116:e95-e98.
11. Tang WH, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007;116:e99-e109.
12. Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-e355.
13. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115:e356-e375.
14. Greaser M, Yamagughi M, Brekke C, et al. Troponin subunits and their interactions. Cold Spring Harbour Symp Quant Biol 1972; 37:235-244.
15. Gupta S, de Lemos JA. Use and misuse of cardiac troponins in clinical practice. Prog Cardiovasc Dis 2007;50:151-165.
16. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96:2953-2958.
17. Sasse S, Brand NJ, Kyprianou P, et al. Troponin 1 gene expression during human cardiac development and in end stage heart failure. Circ Res 1993;72:932-938.
18. O'Brien PJ, Dameron GW, Beck ML, et al. Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sci 1997;47:486-495.
19. Katus HA, Remppis A, Scheffold T, et al. Intra-cellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonperfused myocardial infarction. Am J Cardiol 1991;67:1360-1367.
20. Kremer LC, Bastiaansen BA, Offringa M, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002;38: 686-689.
21. Raderer M, Kornek G, Weinlander G, et al. Serum troponin T levels in adults undergoing anthracycline therapy. J Natl Cancer Inst 1997;89:171.
22. Fink F, Genser N, Fink C, et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995;25:185-189.
23. Kismet E, Varan A, Ayabakan C, et al. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004;42:220-224.
24. Mathew P, Suarez W, Kip K et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001;19:352-359.
25. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005;26:1197-1202.
26. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukaemia. N Engl J Med 2004;351:145-153.
27. Lipschultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641-2648.
28. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-522.
29. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754.
30. Specchia G, Buquicchio C, Pansini N, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukaemia treated with anthracyclines. J Lab Clin Med 2005;145:212-220.
31. Kilickap S, Barista I, Akgul E, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16:798-804.
32. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003;82: 218-222.
33. Missov E, Calzolari C, Davy JM. Cardiac troponin I in patients with heamatologic malignancies. Coron Art Dis 1997;8:538-541.
34. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003;49:248-252.
35. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13:710-715.
36. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328.
37. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review. Clin Chem 2004;50:33-50.
38. Wada A, Tsutamoto T, Matsuda Y, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994;89: 2232-2240.
39. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995;25:227-234.
40. Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231:1145-1147.
41. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-663.
42. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-terminal-pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006;114: 201-208.
43. Nielsen OW, McDonagh TA, Robb SD, et al. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-120.
44. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-1353.
45. Swedberg K, Cleland J, Dargie H, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2005;26:1115-1140.
46. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and nor epinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-2458.
47. Clerico A, Del Ry S, Maffei S, et al. Circulating levels of cardiac natriuretic hormones in healthy adult subjects: Effects of aging and sex. Clin Chem Lab Med 2002;40:371-377.
48. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002;251:228-234.
49. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362-363.
50. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4-9.
51. Pinarli FG, Oǧuz A, Tunaoglu FS, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005;44:370-377.
52. Aggarwal S, Pettersen MD, Bhambhani K, et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007;49:812-816.
53. Germanakis I, Kalmanti M, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 2006;108:212-215.
54. Vogelsang TW, Jensen RJ, Hesse B, et al. BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxicity. Int J Cardiol 2008;29:193-197.
55. Tikanoja T, Riikonen P, Perkkiö M, et al. Serum N terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol 1998;31:73-78.
56. Bauch M, Ester A, Kimura B, et al. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992; 69:1492-1497.
57. Snowden JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000;26:309-313.
58. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000;104:158-163.
59. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001;19:2746-2753.
60. Sandri MT, Salvatici M, Cardinale D, et al. NA-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction? Clin Chem 2005;51:1405-1410.
61. Silber JH. Role of after load reduction in the prevention of late anthracycline cardiomyopathy. Pediatr Blood Cancer 2005;44: 607-613.
62. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820-828.
63. Bryant J, Picot J, Baxter L, et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: A systematic review. Eur J Cancer 2007;43:1959-1966.
64. van Dalen EC, van den Brug M, Caron HN, et al. Anthracycline-induced cardiotoxicity: Comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer 2006;42:3199-3205.